Takeda Pharmaceutical Company Limited and Theravance Biopharma Inc. recently entered a global license, development and commercialization agreement for TD-8954, a potential treatment for gastrointestinal motility disorders like enteral feeding intolerance (EFI).

Nancy Brown, the CEO of the American Heart Association (AHA), recently released a statement about the new sugary drink tax that Philadelphia has implemented in the local area.

The FDA recently released a new form and guidance documents for physicians requesting individual expanded access for, or compassionate use of, investigational drugs and biologics.

The American Society of Health-System Pharmacists (ASHP) recently joined a meeting with the Obama administration at the White House to address the ongoing opioid abuse, overdose and addiction epidemic in the U.S.

The American Academy of Family Physicians (AAFP) recently encouraged improved performance measurement policies in the new payment models that are part of the Medicare Access and CHIP Reauthorization Act (MACRA).

Vifor Pharma, a company under the Galenica group, recently announced that it has broadened its Erythropoiesis Stimulating Agent (ESA) portfolio by granting the commercialization license rights within the U.S. to Retacrit from Pfizer.

The U.S. Food and Drug Administration (FDA) recently approved of a priority review of the biologics license application (BLA) for olaratumab, a medicine designed to treat advanced soft tissue sarcoma (STS).

The Committee for Medicine Products for Human Use (CHMP) branch of the European Medicines Agency recently granted a positive opinion to broaden the indication of Amgen’s Kyprolis (carfilzomib) treatment for relapsed multiple myeloma.

Shire plc recently announced that the Committee for Medicine Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion of Revestive (teduglutide) to treat pediatric short bowl syndrome patients.

AstraZeneca recently announced that it has finished its U.S. licensing agreement for the exclusive U.S. rights to Zurampic, also called lesinurad, as well as the fixed-dose lesinurad and allopurinol combination from Ironwood Pharmaceuticals.

Purdue Pharma LP recently announced that it has entered into a patent agreement with Acura Pharmaceuticals Inc. and Egalet Corporation to settle a variety of patent claims.

BioMarin Pharmaceutical Inc. recently announced its decision to withdraw its Marketing Authorization Application (MAA) for Kyndrisa (drisapersen) from Europe after holding the May 2016 Committee for Medicines Agency (EMA) meeting.

AbbVie, a worldwide biopharmaceutical company, recently announced that officials at the European Commission (EC) have approved Imbruvica to be used as a first-line treatment option for chronic lymphocytic leukemia (CLL).

The Committee for Medicine Products for Human Use (CHMP) branch of the European Medicines Agencies (EMA) recently granted a positive opinion of Zepatier, a Merck product.

Leaders at the U.S. Food and Drug Administration (FDA) recently granted approval of Probuphine, which is the first buprenorphine implant that is designed to treat opioid dependence.

Leaders at the American Medical Association (AMA) recently congratulated the U.S. Food and Drug Administration (FDA) for modifying its Nutrition Facts Label to emphasize the sugar levels in food products.

The American Heart Association recently applauded the draft legislation from the Senate that could end the 'all-or-nothing approach' and implement meaningful use of the Medicare and Medicaid Electronic Health Records Incentive Programs.

The Agency for Healthcare Research and Quality (AHRQ) has developed a program, called the Health Care Safety Hotline project, to improve the quality and safety of medical events for patients throughout the U.S.

The American Heart Association (AHA) recently opened its guidelines-compliant BLS and ACLS courses, which are designed to help attendees better recognize and implement the emergency response system in an emergency situation.

MedImmune, the worldwide biologics research and development branch of AstraZeneca, recently gained Fast Track designation for its MEDI18852, an investigational human monoclonal antibody (mAb), from the U.S. Food and Drug Administration (FDA).